The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Multi-Stakeholder Workshop

Gene and Cell Therapies in Oncology

29 – 30 November 2021, Online workshop

 

Recordings

 

SESSION 1: WHO IS THE GENE AND CELL CANCER-KILLER: DEEP DIVE ON THE GENE AND CELL SCIENTIFIC APPROACHES IN ONCOLOGY

SESSION 2: HOW TO DEVELOP A GENE AND CELL CANCER KILLER: THE CLINICAL TRIALS.

Challenges in timely initiation and conduct of clinical trials in gene and cell therapies in hematoncology. From planning to trial authorisation to patient treatment and follow up

From clinical trials to marketing authorisation of advanced therapies – Martina Schuessler-Lenz (EMA CAT Chair; Paul-Ehrlich-Institut, DE)

Approval pathways for innovative gene & cell therapies – Adnan Jaigirdar (FDA, USA)

Clinical trials with gene and cell therapies – challenges and opportunities. The industry perspective – Laura Pearce (GSK, USA)

Challenges and learnings in conducting clinical trials with gene and cell therapies: the investigator perspective – Michael Hudecek (University of Würzburg, DE) – The speaker did not consent to have his presentation published

Panel Discussion

 

SESSION 3: HOW TO BRING A GENE AND CELL CANCER KILLER TO PATIENTS: HOW TO IMPROVE PATIENT ACCESS

From marketing authorisation to patient access – the rollout from the industry perspective – Bernd Eschgfaeller (Novartis, CH) – The speaker did not consent to have his presentation published

Patient perspective – Kate Morgan (MPE, UK)

HTA perspective and reimbursement models – Carin Uyl-de Groot (Erasmus University Rotterdam, NL)

Panel Discussion

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70